MYSTERIOUS: Rdhl - What They Never Told You

RedHill Biopharma Ltd's (NASDAQ:RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability.  The Company says that based on the new and previously announced data, opaganib's dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of…

  Redhill Biopharma (NASDAQ:RDHL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Redhill Biopharma (NASDAQ:RDHL) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that Redhill Biopharma will report an earnings per share (EPS) of $-0.33.

RedHill Biopharma Ltd (NASDAQ:RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea.  Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million. Redhill is eligible for up to $5.6 million…